LCOR

LCOR is a multifunctional transcriptional coregulator that controls gene expression through context-dependent corepression, coactivation, and chromatin modification (PMID:12535528, PMID:29628311). In its founding role, LCoR is recruited to agonist-bound nuclear receptors including estrogen receptor alpha through a single LXXLL motif and represses receptor signaling by two parallel routes: an HDAC-dependent mechanism involving direct binding to histone deacetylases (including HDAC6 via its central domain) and an HDAC-independent mechanism through recruitment of CtBP corepressors at consensus CtBP-binding motifs (PMID:12535528, PMID:19744931). Beyond nuclear receptors, LCoR uses its C-terminal helix-turn-helix (HTH) domain to engage sequence-specific transcription factors — KLF6 at the CDKN1A and CDH1 promoters, C/EBPβ to suppress adipogenic genes, and RIP140 to restrain breast cancer cell proliferation — combining N-terminal CtBP recruitment and central-domain HDAC recruitment to effect repression (PMID:22277651, PMID:28414308, PMID:28972158). The LCOR locus also encodes PALI1, a PRC2.1-associated subunit that stimulates PRC2 H3K27 methyltransferase activity and defines a PRC2 subtype antagonistic to AEBP2/JARID2-containing PRC2.2, and Pali1-null mice are embryonic-lethal (PMID:29628311). In an opposing transcriptional capacity, LCOR acts as an interferon-independent activator that binds ISRE elements to drive antigen processing/presentation machinery gene expression; this activity is silenced by miR-199a, whose targeting of the LCOR 3'-UTR licenses immune escape and stem-like properties in breast cancer (PMID:28530657, PMID:35301507). LCoR can also operate as a coactivator of PPARγ-RXRα heterodimers at the Muc1 promoter (PMID:29463649).

1. 2003 High

   Established LCoR as a ligand-dependent corepressor by showing how it docks onto activated nuclear receptors and the dual machinery it uses to silence them, defining its founding mechanism.

   Evidence In vitro binding, coactivator-pocket mutagenesis, HDAC-inhibitor (TSA) pharmacology, Co-IP, and confocal colocalization with CtBPs

   PMID:12535528

   Open questions at the time

   • Which specific HDACs were engaged was not fully resolved
   • Genome-wide receptor targets not mapped
2. 2009 High

   Resolved the central-domain HDAC6 interaction and revealed that LCoR-HDAC6 co-recruitment can both repress and, unexpectedly, enhance some endogenous estrogen target genes, indicating context-dependent output.

   Evidence GST pull-down, Co-IP, ChIP/re-ChIP, siRNA knockdown and RT-qPCR in MCF7 cells

   PMID:19744931

   Open questions at the time

   • LCoR and HDAC6 did not co-IP on target genes, leaving the complex composition unclear
   • Basis for gene-specific activation versus repression unexplained
3. 2012 High

   Extended LCoR function beyond nuclear receptors by identifying KLF6 as a direct partner, showing LCoR acts as a corepressor for sequence-specific transcription factors at cell-cycle and adhesion genes.

   Evidence Yeast two-hybrid, Co-IP, ChIP at CDKN1A/CDH1, TSA reporter assays, domain-deletion analysis, siRNA

   PMID:22277651

   Open questions at the time

   • In vivo relevance of KLF6-LCoR repression not tested
   • Whether HTH domain directly contacts KLF6 not mapped at residue level
4. 2017 High

   Mapped the HTH domain as the interaction surface for RIP140 and C/EBPβ, linking LCoR to control of breast cancer proliferation and adipogenesis, and showed miR-199a represses LCOR to attenuate IFN priming and promote stemness.

   Evidence AP-MS, reciprocal Co-IP, PLA, HTH mutagenesis, ChIP, 3'-UTR luciferase reporter, knockdown/overexpression and in vivo tumor-initiation models

   PMID:28414308 PMID:28530657 PMID:28972158

   Open questions at the time

   • Direct structural basis of HTH-partner binding not solved
   • Mechanism by which LCOR primes IFN responses not detailed at this stage
5. 2018 High

   Revealed two new dimensions: the LCOR-encoded PALI1 is a PRC2.1 subunit that stimulates H3K27 methylation and is required for development, and LCoR can act as a coactivator of PPARγ-RXRα, broadening its mechanistic repertoire beyond repression.

   Evidence Biochemical reconstitution and in vitro methyltransferase assays, ChIP-seq, Pali1-null mice; Co-IP, reporter assays, and Lcor-null placenta analysis for PPARγ-RXRα coactivation

   PMID:29463649 PMID:29628311

   Open questions at the time

   • Relationship between PALI1/PRC2 function and the corepressor LCoR isoform not integrated
   • Determinants switching LCoR between corepressor and coactivator modes unknown
6. 2022 High

   Defined LCOR as an IFN-independent transcriptional activator that binds ISRE elements to drive antigen processing/presentation machinery, mechanistically explaining how its miR-199a-mediated loss enables tumor immune escape.

   Evidence ChIP at ISRE elements, genetic gain/loss of function, expression profiling, in vivo immunotherapy tumor models

   PMID:35301507

   Open questions at the time

   • Cofactors enabling ISRE-bound activation versus repression not identified
   • How the same protein selects activator versus corepressor targets unresolved
7. 2025 Medium

   Showed LCOR de-represses PLCL1 by antagonizing RUNX1, restraining lipid accumulation and tumor progression in clear cell renal cell carcinoma, adding a tissue-specific regulatory axis.

   Evidence Co-IP, ChIP-qPCR, reporter assays, gain/loss of function in vitro and in vivo renal tumor models

   PMID:40083699

   Open questions at the time

   • Single-lab finding without reciprocal structural validation of LCOR-RUNX1 binding
   • Whether de-repression involves displacement of corepressors not defined

• The molecular determinants that switch LCOR/PALI1 between corepressor, coactivator, and PRC2-stimulatory functions across cell contexts remain undefined.
• No structural model integrating LXXLL, CtBP, and HTH modules
• No unified explanation for context-dependent activation versus repression
• Relationship between LCoR and PALI1 isoforms in vivo unresolved